Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jennifer Wallet
Observed names:
J Wallet,
J. Wallet,
Wallet, Jennifer
Institutions:
Centre Oscar Lambret,
Centre Hospitalier de Valenciennes
Observed institutions:
University of Pisa,
Centre Hospitalier Universitaire de Lille,
Centre Oscar Lambret,
Centre Hospitalier de Valenciennes
ORCID:
0000-0002-9521-8701
Observed ORCID:
0000-0002-9521-8701
OpenAlex ID:
A5044978652
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
2016
·
Olivier Mir
, Thomas Brodowicz
, et al.
·
The Lancet Oncology
·
295
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
2016
·
Antoine Adenis
, Christelle de la Fouchardiere
, et al.
·
BMC Cancer
·
144
PDF
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
2019
·
Emilie Le Rhun
, Jennifer Wallet
, et al.
·
Neuro-Oncology
·
118
PDF
REGOSARC : Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
2017
·
Vincent Berry
, Laurent Basson
, et al.
·
Cancer
·
49
PDF
Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results
2019
·
Jonathan Olivier
, Laurent Basson
, et al.
·
Frontiers in Oncology
·
34
PDF
Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
2016
·
Antoine Adenis
, Christelle de la Fouchardiere
, et al.
·
BMC Cancer
·
27
PDF
Outcomes of the use of different vulvar flaps for reconstruction during surgery for vulvar cancer
2019
·
Stéphanie Tock
, Jennifer Wallet
, et al.
·
European Journal of Surgical Oncology
·
25
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib
2020
·
Nicolas Penel
, Olivier Mir
, et al.
·
European Journal of Cancer
·
23
PDF
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma
2018
·
Thomas Brodowicz
, Olivier Mir
, et al.
·
European Journal of Cancer
·
22
Decision‐making determinants for breast reconstruction in women over 65 years old
2019
·
Julie Quemener
, Jennifer Wallet
, et al.
·
The Breast Journal
·
19
PDF
Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.
2015
·
Olivier Mir
, Thomas Brodowicz
, et al.
·
Journal of Clinical Oncology
·
15
Lomboaortic Lymphadenectomy in Gynecological Oncology: Laparotomy, Laparoscopy or Robot-Assisted Laparoscopy?
2020
·
Y. Kerbage
, A. Kakkos
, et al.
·
Annals of Surgical Oncology
·
13
PDF
Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy
2021
·
Hind Zaine
, Benjamin Vandendorpe
, et al.
·
Frontiers in Oncology
·
12
PDF
Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
2020
·
Thomas Brodowicz
, Bernadette Liegl-Atzwanger
, et al.
·
Cancers
·
11
PDF
Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series
2025
·
Ludwige Abancourt
, Muhammad Ali
, et al.
·
European Urology Oncology
·
9
The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients
2018
·
M. Longué
, B. Cabarrou
, et al.
·
Annals of Oncology
·
9
PDF
Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial.
2016
·
Nicolas Penel
, Olivier Mir
, et al.
·
Journal of Clinical Oncology
·
9
IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
2023
·
Thomas Le Roy
, Jennifer Wallet
, et al.
·
Frontiers in Oncology
·
6
PDF
Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial
2018
·
E. Le Rhun
, A. Mailliez
, et al.
·
Annals of Oncology
·
6
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial
2025
·
N. Penel
, A. Italiano
, et al.
·
Annals of Oncology
·
5
Incidence and characteristics of chronic postsurgical pain at 6 months after total mastectomy under pectoserratus and interpectoral plane block combined with general anesthesia: a prospective cohort study
2023
·
Vincent Garcia
, Jennifer Wallet
, et al.
·
Regional Anesthesia & Pain Medicine
·
4
Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts.
2022
·
Marie-Cecile Le Deley
, Jean-Yves Blay
, et al.
·
Journal of Clinical Oncology
·
4
Cmet-39. Intra-csf Liposomal Cytarabine Plus Systemic Therapy as Initial Treatment of Breast Cancer Leptomeningeal Metastasis: a Randomised, Open-label Trial
2018
·
Emilie Le Rhun
, Audrey Mailliez
, et al.
·
Neuro-Oncology
·
3
PDF
Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.
2017
·
Nuria Kotecki
, Thomas Brodowicz
, et al.
·
Journal of Clinical Oncology
·
3
2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study
2015
·
C. De La Fouchardiere Fontaniere
, B. Paule
, et al.
·
European Journal of Cancer
·
3
Show more works
View as search
Works count:
52
Citation count:
881
H-index:
12
I10-index:
14
Year
Topic
Type